Iovance Biotherapeutics, Inc.
IOVA
Positions held
Your positionsIOVA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Iovance Biotherapeutics is positioned in a rapidly growing biotechnology sector, focusing on innovative cell therapy treatments that address unmet medical needs.
- Revenue increased by 39% compared to the prior quarter, reaching $99 million.
- Gross margin improved significantly to 56.1%, up from 40.5% in the previous quarter.
- The company faces significant financial challenges, with a negative profit margin of -89.09% indicating ongoing losses.
- Operating margin remains negative at -52.3%, reflecting continued operational inefficiencies.
- Net income for the most recent quarter was -47.315 million, highlighting persistent financial struggles.
Fundamentals
| Market cap | $6.03B | Enterprise value | $5.78B | Trailing P/E | — | Forward P/E | -62.05 |
| PEG | — | Price / book | 8.19 | Beta | 0.76 | Dividend yield | 0.00% |
| Revenue growth | 65.7% | Earnings growth | — | Gross margin | 48.4% | Operating margin | -52.3% |
| Profit margin | -89.1% | ROE | -40.4% | ROA | -20.3% | Debt / equity | 0.06 |
| Current ratio | 4.35 | Free cash flow | -$187.79M | Analyst recommendation | buy | Mean target | $13.30 |
| 52w high | $15.30 | 52w low | $1.76 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $99.3M | $71.4M | $86.8M | $67.5M | $60.0M |
| Op margin | -52.3% | -113.5% | -84.7% | -133.1% | -189.8% |
| Net income | -$47.3M | -$79.0M | -$71.9M | -$91.3M | -$112M |
| Gross margin | 56.1% | 40.5% | 50.3% | 43.0% | 18.5% |
| Gross profit | $55.7M | $28.9M | $43.7M | $29.0M | $11.1M |
| Operating income | -$51.9M | -$81.0M | -$73.5M | -$89.8M | -$114M |
- Revenue +39% vs prior quarter ($99M vs $71M).
- Gross margin 56.1% (was 40.5% prior quarter).
- Operating margin expanded to -52.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $264M | $164M | $1.2M | $0.0M | — |
| Op margin | -151.1% | -240.9% | -38735.0% | — | — |
| Net income | -$391M | -$372M | -$444M | -$396M | — |
| Gross margin | 34.3% | 43.2% | 13.1% | — | — |
| Gross profit | $90.3M | $70.8M | $0.2M | $0.0M | — |
| Operating income | -$398M | -$395M | -$461M | -$399M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-04 · Why Iovance Biotherapeutics (IOVA) Effortlessly Soared 256% in Q3
2026-10-03 · Iovance Biotherapeutics (IOVA) Stock Gets Fair Value Boost On Amtagvi Demand And Margin Outlook
2026-10-01 · Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
2026-09-30 · IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
2026-09-30 · Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
2026-09-30 · Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
2026-09-30 · Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
2026-09-30 · Iovance Biotherapeutics (IOVA) Eyes 60% Revenue Growth, Shares Jump 31%
2026-09-29 · Apple, Meta, Iovance, Carnival, Fair Isaac, Bloom Energy, SpaceX, and More Stocks That Explain Today’s Market
2026-09-29 · Sector Update: Healthcare Stocks Softer Late Afternoon
2026-09-29 · Update: Iovance Biotherapeutics Shares Jump After 2026 Revenue Guidance Raised
2026-09-29 · Sector Update: Healthcare Stocks Decline Tuesday Afternoon
Price (daily)
Full chart · RSI · MACD · patterns